Some U.S. biotech companies are debating on relocating their early-stage trials of new medicines outside the U.S. due to worries that layoffs and policy changes at the U.S. Food and Drug Administration by the Trump administration may lead to delays in regulatory reviews, Maggic Fick of Reuters reports, citing executives, investors, and consultants. Publicly traded companies in the space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Trump’s drug-price crackdown may lead to minor concessions, WSJ reports
- JPMorgan sees ‘most favored nation’ drug order facing ‘significant push back’
- Pharma Stocks Rally despite Trump’s Plan to Cut Drug Prices
- White House publishes Trump executive order aimed at lowering drug prices
- AstraZeneca’s Trixeo Aerosphere approved for use in UK with propellant